Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multiple Sclerosis Topic Center

Featured Article

News
Neurologist Recognized for Pioneering MS Research and Treatment Strategies
04/24/2024
Hannah Musick
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the...
04/24/2024
First Report Managed Care
News
Trial to Test CAR T-Cell Therapy for Refractory Progressive MS
03/18/2024
Jolynn Tumolo
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
An autologous, fully human CD19...
03/18/2024
First Report Managed Care
News
Dairy, Gluten Show No Major Effect on MS Activity and Quality of Life
02/15/2024
Jolynn Tumolo
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Dairy and gluten intake had no...
02/15/2024
First Report Managed Care
News
Risk of MS Lower in People Living With HIV
01/10/2024
Jolynn Tumolo
People living with HIV have a lower risk of multiple sclerosis, according to an article published ahead of print in Annals of Neurology.
People living with HIV have a lower risk of multiple sclerosis, according to an article published ahead of print in Annals of Neurology.
People living with HIV have a...
01/10/2024
First Report Managed Care
News
Cautious Excitement Follows First-in-Human Stem Cell Trial for Progressive MS
12/14/2023
Jolynn Tumolo
Fifteen patients with secondary progressive multiple sclerosis (MS) showed stability in lesion load, brain activity, and clinical and laboratory outcomes, with no serious adverse events, 12 months after receiving an injection of human stem...
Fifteen patients with secondary progressive multiple sclerosis (MS) showed stability in lesion load, brain activity, and clinical and laboratory outcomes, with no serious adverse events, 12 months after receiving an injection of human stem...
Fifteen patients with secondary...
12/14/2023
First Report Managed Care
News
High-Efficacy Therapies for Treatment-Naïve Patients With Relapsing–Remitting MS
12/05/2023
Hannah Musick
“By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient,” said researchers.
“By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient,” said researchers.
“By minimizing the accumulation...
12/05/2023
First Report Managed Care
News
Novel Neurotherapeutic Class May Prove Beneficial for Both Relapsing, Progressive MS
11/22/2023
Jolynn Tumolo
The review provides a summary of the evolving landscape of multiple sclerosis treatment options, including disease-modifying therapies (DMTs), investigative remyelinating strategies, impending neurotherapeutics, and stem cell therapies.
The review provides a summary of the evolving landscape of multiple sclerosis treatment options, including disease-modifying therapies (DMTs), investigative remyelinating strategies, impending neurotherapeutics, and stem cell therapies.
The review provides a summary of...
11/22/2023
First Report Managed Care
News
Patients With MS Switching to Teriflunomide: Characteristics, Utilization, and Relapses
11/09/2023
Hannah Musick
“Switching to teriflunomide from existing DMTs in patients with relapsing MS resulted in a reduction in outpatient HCRU in this analysis of US claims data,” said researchers.
“Switching to teriflunomide from existing DMTs in patients with relapsing MS resulted in a reduction in outpatient HCRU in this analysis of US claims data,” said researchers.
“Switching to teriflunomide from...
11/09/2023
First Report Managed Care
News
Exploring Multiple Sclerosis Disparities: A Focus on Black and Hispanic Populations in the US
10/18/2023
Hannah Musick
A narrative review explores the patterns of disease presentation, genetic considerations, response to treatment, social determinants of health, and health care utilization in Black and Hispanic persons with multiple sclerosis in the US,...
A narrative review explores the patterns of disease presentation, genetic considerations, response to treatment, social determinants of health, and health care utilization in Black and Hispanic persons with multiple sclerosis in the US,...
A narrative review explores the...
10/18/2023
First Report Managed Care
News
Comparing the Effectiveness and Cost of DMTs vs Ozanimod for MS Patients
10/05/2023

Danielle Sposato

Danielle Sposato
Findings showed that ozanimod had lower annual drug costs per person than many other DMTs, making it more cost-effective in terms of drug costs per relapse avoided.
Findings showed that ozanimod had lower annual drug costs per person than many other DMTs, making it more cost-effective in terms of drug costs per relapse avoided.
Findings showed that ozanimod...
10/05/2023
First Report Managed Care
News
Heterogeneity of Treatment Effect in MS Trials Should Include Multiple Factors
09/29/2023
Jolynn Tumolo
The much recognized diversity in outcomes among patients with multiple sclerosis (MS), accounted for by genes, age, and other key patient factors, may extend to therapeutic responses to treatment. Consequently, evaluating possible...
The much recognized diversity in outcomes among patients with multiple sclerosis (MS), accounted for by genes, age, and other key patient factors, may extend to therapeutic responses to treatment. Consequently, evaluating possible...
The much recognized diversity in...
09/29/2023
First Report Managed Care

Newsfeed

News
Neurologist Recognized for Pioneering MS Research and Treatment Strategies
04/24/2024
Hannah Musick
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the...
04/24/2024
First Report Managed Care
News
Trial to Test CAR T-Cell Therapy for Refractory Progressive MS
03/18/2024
Jolynn Tumolo
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
An autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate recently received clearance from the US Food and Drug Administration (FDA) as an investigational new drug for the treatment of patients with refractory...
An autologous, fully human CD19...
03/18/2024
First Report Managed Care
News
Dairy, Gluten Show No Major Effect on MS Activity and Quality of Life
02/15/2024
Jolynn Tumolo
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Dairy and gluten intake had no...
02/15/2024
First Report Managed Care
News
Risk of MS Lower in People Living With HIV
01/10/2024
Jolynn Tumolo
People living with HIV have a lower risk of multiple sclerosis, according to an article published ahead of print in Annals of Neurology.
People living with HIV have a lower risk of multiple sclerosis, according to an article published ahead of print in Annals of Neurology.
People living with HIV have a...
01/10/2024
First Report Managed Care
News
Cautious Excitement Follows First-in-Human Stem Cell Trial for Progressive MS
12/14/2023
Jolynn Tumolo
Fifteen patients with secondary progressive multiple sclerosis (MS) showed stability in lesion load, brain activity, and clinical and laboratory outcomes, with no serious adverse events, 12 months after receiving an injection of human stem...
Fifteen patients with secondary progressive multiple sclerosis (MS) showed stability in lesion load, brain activity, and clinical and laboratory outcomes, with no serious adverse events, 12 months after receiving an injection of human stem...
Fifteen patients with secondary...
12/14/2023
First Report Managed Care
News
High-Efficacy Therapies for Treatment-Naïve Patients With Relapsing–Remitting MS
12/05/2023
Hannah Musick
“By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient,” said researchers.
“By minimizing the accumulation of neurological damage early in the disease course, early treatment with HETs may enhance long-term clinical outcomes over the lifetime of the patient,” said researchers.
“By minimizing the accumulation...
12/05/2023
First Report Managed Care
News
Novel Neurotherapeutic Class May Prove Beneficial for Both Relapsing, Progressive MS
11/22/2023
Jolynn Tumolo
The review provides a summary of the evolving landscape of multiple sclerosis treatment options, including disease-modifying therapies (DMTs), investigative remyelinating strategies, impending neurotherapeutics, and stem cell therapies.
The review provides a summary of the evolving landscape of multiple sclerosis treatment options, including disease-modifying therapies (DMTs), investigative remyelinating strategies, impending neurotherapeutics, and stem cell therapies.
The review provides a summary of...
11/22/2023
First Report Managed Care
News
Patients With MS Switching to Teriflunomide: Characteristics, Utilization, and Relapses
11/09/2023
Hannah Musick
“Switching to teriflunomide from existing DMTs in patients with relapsing MS resulted in a reduction in outpatient HCRU in this analysis of US claims data,” said researchers.
“Switching to teriflunomide from existing DMTs in patients with relapsing MS resulted in a reduction in outpatient HCRU in this analysis of US claims data,” said researchers.
“Switching to teriflunomide from...
11/09/2023
First Report Managed Care
News
Exploring Multiple Sclerosis Disparities: A Focus on Black and Hispanic Populations in the US
10/18/2023
Hannah Musick
A narrative review explores the patterns of disease presentation, genetic considerations, response to treatment, social determinants of health, and health care utilization in Black and Hispanic persons with multiple sclerosis in the US,...
A narrative review explores the patterns of disease presentation, genetic considerations, response to treatment, social determinants of health, and health care utilization in Black and Hispanic persons with multiple sclerosis in the US,...
A narrative review explores the...
10/18/2023
First Report Managed Care
News
Comparing the Effectiveness and Cost of DMTs vs Ozanimod for MS Patients
10/05/2023

Danielle Sposato

Danielle Sposato
Findings showed that ozanimod had lower annual drug costs per person than many other DMTs, making it more cost-effective in terms of drug costs per relapse avoided.
Findings showed that ozanimod had lower annual drug costs per person than many other DMTs, making it more cost-effective in terms of drug costs per relapse avoided.
Findings showed that ozanimod...
10/05/2023
First Report Managed Care
News
Keratoconus Appears to be Associated With Demodex Mites
05/16/2024
Jolynn Tumolo
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
Keratoconus, an eye disorder...
05/16/2024
First Report Managed Care
News
Hospital Costs May Be Higher for Patients With Private Insurance
05/14/2024
Hannah Musick
A recent research report reveals that individuals with private health insurance pay 254% more for hospital procedures than Medicare rates, leading to potentially increased costs for millions of Americans.
A recent research report reveals that individuals with private health insurance pay 254% more for hospital procedures than Medicare rates, leading to potentially increased costs for millions of Americans.
A recent research report reveals...
05/14/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
Demodex Infestation Found in 9 of 10 Eye Clinic Patients Using 2-Minute Technique
05/09/2024
Jolynn Tumolo
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the...
05/09/2024
First Report Managed Care
News
Debate Emerges Over FDA's Plan to Regulate Laboratory Medical Tests
05/03/2024
Hannah Musick
The FDA's new regulations on laboratory-developed tests have sparked debate over access to innovative tests and patient care in the medical field, with opponents arguing that increased oversight could hinder the development of crucial new...
The FDA's new regulations on laboratory-developed tests have sparked debate over access to innovative tests and patient care in the medical field, with opponents arguing that increased oversight could hinder the development of crucial new...
The FDA's new regulations on...
05/03/2024
First Report Managed Care
News
Analysis Shows Proposed CMS ‘Best Price’ Rule May Increase Rebate Liability, Impacting Medicaid
04/26/2024
Dean Celia
A proposed rule from Centers for Medicare & Medicaid Services (CMS), “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program,” has been in the spotlight recently. Major health...
A proposed rule from Centers for Medicare & Medicaid Services (CMS), “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program,” has been in the spotlight recently. Major health...
A proposed rule from Centers for...
04/26/2024
First Report Managed Care
News
Rebalancing Coagulation Pathways and Human Factor 9 Gene Knock-In Strategy Identified for Hemophilia B
04/25/2024

Grace Taylor

Grace Taylor
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular...
04/25/2024
First Report Managed Care
News
Neurologist Recognized for Pioneering MS Research and Treatment Strategies
04/24/2024
Hannah Musick
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the 2024 John Dystel prize for her groundbreaking research on sex differences in multiple sclerosis (MS), advancing women's health.
Dr Rhonda Voskuhl received the...
04/24/2024
First Report Managed Care
News
Chicago Sky Blue May be Considered as a Diagnostic Stain for Visualizing Demodex in Patients With Demodex Blepharitis
04/24/2024
Lisa Kuhns, PhD
Chicago sky blue is a promising stain that can identify and quantify the number of Demodex mites in patients with Demodex blepharitis, according to a study published in PeerJ.
Chicago sky blue is a promising stain that can identify and quantify the number of Demodex mites in patients with Demodex blepharitis, according to a study published in PeerJ.
Chicago sky blue is a promising...
04/24/2024
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care

Advertisement

Advertisement

FRMC Volume 21, Issue 1

Current Issue

March 2024
Volume 21
Issue 1
Current Issue
Issue Archive

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement